|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: C14orf37 |
Gene summary for C14ORF37 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | C14orf37 | Gene ID | 145407 |
| Gene name | armadillo like helical domain containing 4 | |
| Gene Alias | C14orf37 | |
| Cytomap | 14q23.1 | |
| Gene Type | protein-coding | GO ID | GO:0005575 | UniProtAcc | B2RUU6 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 145407 | C14orf37 | P1T-E | Human | Esophagus | ESCC | 2.75e-04 | 2.67e-01 | 0.0875 |
| 145407 | C14orf37 | P2T-E | Human | Esophagus | ESCC | 1.75e-23 | 4.17e-01 | 0.1177 |
| 145407 | C14orf37 | P4T-E | Human | Esophagus | ESCC | 1.72e-08 | 2.50e-01 | 0.1323 |
| 145407 | C14orf37 | P5T-E | Human | Esophagus | ESCC | 2.65e-04 | 1.74e-01 | 0.1327 |
| 145407 | C14orf37 | P8T-E | Human | Esophagus | ESCC | 4.70e-10 | 1.96e-01 | 0.0889 |
| 145407 | C14orf37 | P10T-E | Human | Esophagus | ESCC | 8.26e-17 | 3.46e-01 | 0.116 |
| 145407 | C14orf37 | P11T-E | Human | Esophagus | ESCC | 3.00e-05 | 2.69e-01 | 0.1426 |
| 145407 | C14orf37 | P12T-E | Human | Esophagus | ESCC | 1.42e-08 | 9.73e-02 | 0.1122 |
| 145407 | C14orf37 | P15T-E | Human | Esophagus | ESCC | 4.96e-07 | 2.25e-01 | 0.1149 |
| 145407 | C14orf37 | P16T-E | Human | Esophagus | ESCC | 1.73e-14 | 2.22e-01 | 0.1153 |
| 145407 | C14orf37 | P20T-E | Human | Esophagus | ESCC | 1.94e-07 | 2.22e-01 | 0.1124 |
| 145407 | C14orf37 | P22T-E | Human | Esophagus | ESCC | 1.65e-13 | 2.34e-01 | 0.1236 |
| 145407 | C14orf37 | P23T-E | Human | Esophagus | ESCC | 3.58e-02 | 1.30e-01 | 0.108 |
| 145407 | C14orf37 | P26T-E | Human | Esophagus | ESCC | 8.29e-21 | 4.39e-01 | 0.1276 |
| 145407 | C14orf37 | P27T-E | Human | Esophagus | ESCC | 9.18e-08 | 2.37e-01 | 0.1055 |
| 145407 | C14orf37 | P30T-E | Human | Esophagus | ESCC | 1.72e-11 | 4.39e-01 | 0.137 |
| 145407 | C14orf37 | P32T-E | Human | Esophagus | ESCC | 1.64e-04 | 7.24e-02 | 0.1666 |
| 145407 | C14orf37 | P37T-E | Human | Esophagus | ESCC | 9.18e-03 | 9.73e-02 | 0.1371 |
| 145407 | C14orf37 | P39T-E | Human | Esophagus | ESCC | 2.96e-02 | 9.23e-02 | 0.0894 |
| 145407 | C14orf37 | P47T-E | Human | Esophagus | ESCC | 1.81e-02 | 1.28e-01 | 0.1067 |
| Page: 1 2 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| C14orf37 | SNV | Missense_Mutation | c.145N>G | p.Lys49Glu | p.K49E | Q86TY3 | protein_coding | tolerated(0.14) | benign(0.058) | TCGA-A1-A0SH-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | tc | SD | |
| C14orf37 | SNV | Missense_Mutation | c.1229N>T | p.Ser410Phe | p.S410F | Q86TY3 | protein_coding | deleterious(0.02) | benign(0.086) | TCGA-A2-A0YK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | |
| C14orf37 | SNV | Missense_Mutation | novel | c.1540N>C | p.Ser514Pro | p.S514P | Q86TY3 | protein_coding | tolerated(0.17) | benign(0.027) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| C14orf37 | SNV | Missense_Mutation | rs772692558 | c.1711N>T | p.Pro571Ser | p.P571S | Q86TY3 | protein_coding | tolerated(0.2) | benign(0.053) | TCGA-AN-A0G0-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| C14orf37 | SNV | Missense_Mutation | c.214G>A | p.Glu72Lys | p.E72K | Q86TY3 | protein_coding | deleterious(0.02) | benign(0.046) | TCGA-AR-A1AP-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | anastrozole | SD | |
| C14orf37 | insertion | Frame_Shift_Ins | novel | c.2037_2038insTACCTTGTCAAACACGATTTCATTTCAGCAGCTAGGGTGGCCAGAC | p.Thr680TyrfsTer72 | p.T680Yfs*72 | Q86TY3 | protein_coding | TCGA-A8-A08H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
| C14orf37 | insertion | Nonsense_Mutation | novel | c.993_994insCAAGTTTACTTCAGTTCTTCATAGAACT | p.Asp332GlnfsTer8 | p.D332Qfs*8 | Q86TY3 | protein_coding | TCGA-AN-A0FK-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD | ||
| C14orf37 | insertion | Nonsense_Mutation | novel | c.571_572insTAGTGTAATGTATACATGCTCATTCCAAATTGTTTTGGAA | p.Ser191LeufsTer3 | p.S191Lfs*3 | Q86TY3 | protein_coding | TCGA-AO-A0JB-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cyclophosphamide | SD | ||
| C14orf37 | insertion | Nonsense_Mutation | novel | c.702_703insATGTCATCAAATTTTGATAAAACAAATTAATGGAA | p.Ser235MetfsTer10 | p.S235Mfs*10 | Q86TY3 | protein_coding | TCGA-B6-A0IK-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | PD | ||
| C14orf37 | SNV | Missense_Mutation | rs761546306 | c.245N>T | p.Ser82Leu | p.S82L | Q86TY3 | protein_coding | deleterious(0.04) | benign(0.011) | TCGA-EK-A2RB-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 6 7 8 9 10 11 12 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |